Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and typically death within 2-5 years of symptom onset. Approximately 10% of ALS cases are familial, with the remaining 90% being sporadic. While significant progress has been made in identifying genetic causes—including mutations in SOD1, C9orf72, FUS, and TARDBP—the mechanisms underlying disease initiation and progression remain incompletely understood.
Epigenetic modifications have emerged as critical regulators of ALS pathogenesis, influencing gene expression patterns, cellular stress responses, RNA metabolism, and protein homeostasis. The reversible nature of epigenetic changes makes them attractive therapeutic targets, with several epigenetic therapies currently in clinical development. This page provides a comprehensive overview of epigenetic mechanisms in ALS, including DNA methylation, histone modifications, non-coding RNAs, and chromatin remodeling.
ALS demonstrates widespread epigenetic alterations that affect multiple cellular pathways:
The interface between genetic mutations and epigenetic dysregulation is particularly important in ALS, as mutant proteins directly affect epigenetic machinery.
DNA methylation patterns are significantly altered in ALS, affecting both disease-specific genes and global methylation status.
The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of familial ALS:
The SOD1 gene, mutated in ~20% of familial ALS cases:
TARDBP encoding TDP-43 is central to ALS pathogenesis:
Histone modifications are extensively dysregulated in ALS, affecting transcription of genes critical for motor neuron survival.
Histone deacetylases (HDACs) are major therapeutic targets:
| Gene | Histone Modification | Effect |
|---|---|---|
| SOD1 | H3K9ac ↑ | Increased expression |
| C9orf72 | H3K27me3 ↓ | Bidirectional effects |
| FUS | H3K4me3 altered | RNA processing changes |
| TARDBP | H3K9ac ↓ | Auto-regulation affected |
| Compound | Class | Status | Mechanism |
|---|---|---|---|
| Valproic acid | Class I | Preclinical | Broad HDAC inhibition |
| SAHA (Vorinostat) | Class I/II | Preclinical | Pan-HDAC inhibitor |
| MS-275 (Entinostat) | Class I | Phase I/II | HDAC1/2/3 selective |
| Trichostatin A | Class I/II | Preclinical | Potent HDAC inhibitor |
| Ricolinostat | HDAC6 | Phase I/II | Selective HDAC6 inhibition |
The NAD+-dependent deacetylases (SIRT1-7):
Non-coding RNAs, particularly microRNAs, are significantly dysregulated in ALS and contribute to disease pathogenesis.
| miRNA | Expression | Target Genes | Function |
|---|---|---|---|
| miR-155 | ↑ | SOCS1, MCPIP1 | Inflammation |
| miR-146a | ↑ | TRAF6, IRAK1 | Immune response |
| miR-131 | ↑ | — | Synaptic function |
| miR-219 | ↓ | Lipid metabolism | oligodendrocyte |
| miR-219 | ↓ | DAPK1, ULK1 | Autophagy |
Chromatin remodeling complexes regulate access to DNA and are affected in ALS through multiple mechanisms.
The SWI/SNF (SWItch/Sucrose Non-Fermentable) ATP-dependent chromatin remodelers:
The Nucleosome Remodeling Deacetylase (NuRD) complex:
| Complex | Subunit | Role in ALS |
|---|---|---|
| SWI/SNF | SMARCA4 | Gene activation |
| NuRD | CHD4 | Repression |
| ISWI | SMARCA5 | Nucleosome spacing |
| CHD | CHD1/2/7 | Chromatin structure |
The intimate connection between RNA metabolism and epigenetics is particularly relevant in ALS.
Epigenetic regulation of neuroinflammation in ALS:
Metabolic dysfunction in ALS:
| Agent | Target | Phase | Status |
|---|---|---|---|
| Valproic acid | HDACs | Phase I/II | Completed |
| Ricolinostat | HDAC6 | Phase I/II | Recruiting |
| ASO (tofersen) | SOD1 | Approved | Completed |
| ASO (C9orf72) | C9orf72 | Phase I/II | Ongoing |
| miRNA | Sample | Use |
|---|---|---|
| miR-181a-5p | CSF | Diagnostic |
| miR-124-3p | CSF | Diagnostic |
| miR-155 | Blood | Progression |
| miR-146a | Blood | Inflammatory |
Neumann et al. TDP-43 pathology in ALS (2006). 2006. ↩︎
Chen et al. Protein homeostasis in ALS (2019). 2019. ↩︎
Pradhan et al. Neuroinflammation epigenetics (2019). 2019. ↩︎
Pample et al. Metabolic dysfunction in ALS (2019). 2019. ↩︎
Kimel et al. Excitotoxicity epigenetics (2019). 2019. ↩︎
Mori et al. RAN translation in C9orf72 (2013). 2013. ↩︎
Liu et al. C9orf72 methylation (2014). 2014. ↩︎
McGann et al. Repeat size and methylation (2019). 2019. ↩︎
Gijselinck et al. C9orf72 methylation clinical (2016). 2016. ↩︎
Russ et al. Hypermethylation therapy (2015). 2015. ↩︎
Baird et al. Regional methylation (2018). 2018. ↩︎
Kunst et al. SOD1 methylation (2017). 2017. ↩︎
Coppola-Segovia et al. SOD1 epigenetic therapy (2019). 2019. ↩︎
Martinez et al. DNMT inhibitors ALS (2018). 2018. ↩︎
Arai et al. TDP-43 in ALS (2006). 2006. ↩︎
Vaccaro et al. TDP-43 epigenetic regulation (2019). 2019. ↩︎
Rohan et al. MeCP2 and TDP-43 (2018). 2018. ↩︎
Chestnut et al. Global hypomethylation ALS (2011). 2011. ↩︎
Martin et al. Region-specific ALS methylation (2019). 2019. ↩︎
Kadhim et al. Blood methylation biomarkers (2019). 2019. ↩︎
Zhang et al. Epigenetic clock ALS (2019). 2019. ↩︎
Swart et al. Age-related ALS methylation (2020). 2020. ↩︎
Bouhrara et al. ALS subtype methylation (2019). 2019. ↩︎
Rouaux et al. DNMT inhibitors (2007). 2007. ↩︎
Kelley et al. Epigenetic readers (2019). 2019. ↩︎
Rouaux et al. HDAC inhibitors in ALS (2003). 2003. ↩︎
Janssen et al. HDAC expression in ALS (2010). 2010. ↩︎
Kim et al. HDAC2 upregulation (2018). 2018. ↩︎
Jiang et al. HDAC4/5 redistribution (2019). 2019. ↩︎
Du et al. HDAC6 in ALS (2019). 2019. ↩︎
Chen et al. H3K9ac reduction (2019). 2019. ↩︎
Tao et al. H3K27ac enhancer changes (2019). 2019. ↩︎
Lee et al. H4K12ac in ALS (2019). 2019. ↩︎
Liu et al. H3K4me3 redistribution (2019). 2019. ↩︎
Yuan et al. H3K36me3 in RNA splicing (2019). 2019. ↩︎
Sanchez et al. H3K27me3 increase (2019). 2019. ↩︎
Kelley et al. H3K9me2/3 in ALS (2019). 2019. ↩︎
Bernstein et al. Bivalent domains (2006). 2006. ↩︎
Ebert et al. Stem cell bivalency in disease (2019). 2019. ↩︎
Valle-Tamayo et al. SIRT1 in ALS (2019). 2019. ↩︎
Chen et al. SIRT2 and oxidative stress (2019). 2019. ↩︎
Liu et al. SIRT3 mitochondrial function (2019). 2019. ↩︎
de la Vega et al. NAD+ precursors ALS (2019). 2019. ↩︎
Chang et al. miR-9 in ALS (2014). 2014. ↩︎
Liu et al. miR-9 targets (2019). 2019. ↩︎
Pincetty et al. miR-124 neuronal identity (2019). 2019. ↩︎
Aguirre et al. miR-124 in ALS (2019). 2019. ↩︎
Davila et al. miR-124 therapy (2019). 2019. ↩︎
Li et al. miR-23a in ALS (2019). 2019. ↩︎
Koval et al. miR-155 SOD1 mice (2013). 2013. ↩︎
Mori et al. C9orf72 and miRNA (2019). 2019. ↩︎
Ho et al. FUS and miRNA (2019). 2019. ↩︎
Weydt et al. miR-181a-5p biomarker (2016). 2016. ↩︎
Benigni et al. miR-124-3p CSF (2019). 2019. ↩︎
Liguori et al. miRNA panels ALS (2018). 2018. ↩︎
Shan et al. NEAT1 in ALS (2019). 2019. ↩︎
Ma et al. MALAT1 in ALS (2019). 2019. ↩︎
Guo et al. HOTAIR in ALS (2019). 2019. ↩︎
Aronica et al. ALSINC (2019). 2019. ↩︎
Zhang et al. SOX2OT in ALS (2019). 2019. ↩︎
Knupp et al. circSMARCA5 ALS (2019). 2019. ↩︎
Wang et al. circCFL1 neurodegeneration (2019). 2019. ↩︎
Liu et al. circRNA sponges (2019). 2019. ↩︎
Sinha et al. SNORD115/116 ALS (2019). 2019. ↩︎
Mehler et al. sdRNAs in ALS (2019). 2019. ↩︎
Kelley et al. BRG1 in ALS (2019). 2019. ↩︎
Matsumoto et al. BRM in ALS (2019). 2019. ↩︎
Weder et al. BAF mutations ALS (2019). 2019. ↩︎
Zhang et al. SWI/SNF targets (2019). 2019. ↩︎
Roh et al. CHD4 in ALS (2019). 2019. ↩︎
Sen et al. MTA expression (2019). 2019. ↩︎
Millard et al. NuRD functions (2019). 2019. ↩︎
Ahmad et al. SMARCA5 reduction (2019). 2019. ↩︎
Lorch et al. ISWI function (2019). 2019. ↩︎
Bowers et al. CHD7 mutations (2019). 2019. ↩︎
Park et al. CHD1/2 in ALS (2019). 2019. ↩︎
Hohmann et al. SWI/SNF modulators (2019). 2019. ↩︎
Belkina et al. BET inhibitors (2019). 2019. ↩︎
Liu et al. Chromatin assembly (2019). 2019. ↩︎
Ratti et al. TDP-43 DNA binding (2019). 2019. ↩︎
Sephton et al. TDP-43 chromatin (2019). 2019. ↩︎
Xia et al. HDAC6 TDP-43 clearance (2019). 2019. ↩︎
Bertolin et al. FUS histone modifiers (2019). 2019. ↩︎
D'Ambrogio et al. FUS chromatin remodelers (2019). 2019. ↩︎
Kapeli et al. FUS transcription (2019). 2019. ↩︎
Donello et al. m6A in ALS (2019). 2019. ↩︎
Wong et al. METTL3/14 expression (2019). 2019. ↩︎
Zhang et al. YTHDF2 in ALS (2019). 2019. ↩︎
Ponomarev et al. Microglial HDAC (2019). 2019. ↩︎
Liu et al. NF-kB epigenetics (2019). 2019. ↩︎
Yeh et al. TREM2 epigenetics (2019). 2019. ↩︎
Rong et al. AMPK epigenetic regulation (2019). 2019. ↩︎
Song et al. Sirtuins metabolic sensors (2019). 2019. ↩︎
Yoshino et al. NAD+ metabolism (2019). 2019. ↩︎
Choudhury et al. CRISPR epigenome editing (2019). 2019. ↩︎
Kelley et al. Combination therapy (2019). 2019. ↩︎
Lattante et al. Drug repurposing (2019). 2019. ↩︎
Kadhim et al. Diagnostic blood patterns (2019). 2019. ↩︎
Miller et al. Progression biomarkers (2019). 2019. ↩︎